Chuang Hui-Yen, Tyan Yeu-Sheng, Hwang Jeng-Jong, Shih Kuang-Chung, Lin Wei-Chan
Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei 112, Taiwan, R.O.C.
Department of Medical Imaging, Chung Shan Medical University Hospital, Taichung 402, Taiwan, R.O.C.
Oncol Lett. 2021 Apr;21(4):337. doi: 10.3892/ol.2021.12598. Epub 2021 Feb 26.
Hepatocellular carcinoma (HCC) is difficult to diagnose at an early stage, and its prognosis is generally poor. Sorafenib is the primary treatment for unresectable advanced HCC and targets multiple receptor tyrosine kinases. However, sorafenib only extends the average survival time by 3 months. This observation indicates that sorafenib may need to be combined with other treatments to further improve outcomes. We previously showed that combination of sorafenib with radiotherapy (RT) enhances tumor inhibition in subcutaneous HCC mouse models compared with monotherapy. The present study demonstrated that combining sorafenib and RT could suppress tumor growth in an orthotopic HCC model by regulating apoptosis and NF-κB-related pathways. Moreover, decreased numbers of visible liver tumors and a smaller percentage of spleen metastases were found in the combination group. A transient drop in body weight was initially observed after RT, but progressive recovery of body weight occurred. The current study showed that the combination of sorafenib and RT could be a safe strategy for HCC treatment.
肝细胞癌（HCC）很难在早期被诊断出来，并且其预后通常较差。索拉非尼是不可切除的晚期HCC的主要治疗方法，它作用于多种受体酪氨酸激酶。然而，索拉非尼仅能将平均生存时间延长3个月。这一观察结果表明，索拉非尼可能需要与其他治疗方法联合使用，以进一步改善治疗效果。我们之前表明，与单一疗法相比，索拉非尼与放疗（RT）联合使用可增强皮下HCC小鼠模型中的肿瘤抑制作用。本研究表明，联合使用索拉非尼和放疗可通过调节凋亡和NF-κB相关通路来抑制原位HCC模型中的肿瘤生长。此外，联合治疗组中可见肝肿瘤数量减少，脾转移百分比降低。放疗后最初观察到体重短暂下降，但随后体重逐渐恢复。当前研究表明，索拉非尼与放疗联合使用可能是一种安全的HCC治疗策略。
